Viking Therapeutics Inc. (VKTX)

8.22
NASDAQ : Health Technology
Prev Close 8.60
Day Low/High 8.05 / 8.66
52 Wk Low/High 3.69 / 24.00
Avg Volume 2.60M
Exchange NASDAQ
Shares Outstanding 71.46M
Market Cap 614.56M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Viking Therapeutics Shows How Quickly This Market Can Turn

Viking Therapeutics Shows How Quickly This Market Can Turn

If you are trying to pick stocks for the longer term it can be quite challenging right now.

This Is Not Just a Market of Oversold Bounces Now

This Is Not Just a Market of Oversold Bounces Now

What is most interesting about the action today is a spike in the speculative action.

My Stock of the Week: ENDRA Life Sciences

My Stock of the Week: ENDRA Life Sciences

I'm simply focusing on individual stocks at this point and am not too concerned about the macro picture.

It Was a Very Rough Week

It Was a Very Rough Week

Just when you thought the worst was over another wave of selling would hit.

Is the Market Washed Out and Ready for Another Upcycle?

Is the Market Washed Out and Ready for Another Upcycle?

One very encouraging sign Friday is relative outperformance by names that have lately been the weakest.

CAT Stock Gets Thrown Into the Dumpster

CAT Stock Gets Thrown Into the Dumpster

This stock can become much cheaper if there is a major cycle turn occurring.

6 Steps for Dealing With a Market That Can't Be Trusted

6 Steps for Dealing With a Market That Can't Be Trusted

They include holding a high level of cash, keeping stops tight and being patient.

Netflix Is Tonight's Big Report: Here's How I Would Play It

Netflix Is Tonight's Big Report: Here's How I Would Play It

This is a battleground stock that has made big moves in both directions on earnings in the past.

Square Continues to See Extreme Pressure

Square Continues to See Extreme Pressure

If you are interested in Square longer term be patient and wait for the drama to end.

There's Nothing Very Attractive About GE

There's Nothing Very Attractive About GE

It's an interesting story but there are better places for your funds.

FedEx's Report Was Soft, but the Guidance Isn't Bad

FedEx's Report Was Soft, but the Guidance Isn't Bad

It is likely that value buyers will be looking for entry soon as the stock tests the $240 area.

Six Biotechnology Names on My Watch List

Six Biotechnology Names on My Watch List

After recent weakness in the biotech sector, here are some names to start watching.

A Lesson to Learn From Thursday's Market Action

A Lesson to Learn From Thursday's Market Action

You don't have to be Sigmund Freud to understand the psychology here.

Overall the Market Is in Good Shape

Overall the Market Is in Good Shape

The action started a little slowly this morning but market players shook off early jitters and are doing a nice job of building on yesterday's momentum.

There Is Still a Strong Appetite for Big Moving Speculative Names

There Is Still a Strong Appetite for Big Moving Speculative Names

There isn't any big mystery about what is going on here.

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.

Choppy Market Action This Morning

Choppy Market Action This Morning

The good news is that there is some stock picking that is working well.

How Unusual This Market Action Is

How Unusual This Market Action Is

Despite this huge move over the last five days the indices still have more work to do to make it back to highs.

Traders Need to Adapt to a New Reality

Traders Need to Adapt to a New Reality

The volatility trade that propped up markets is no longer available.

The Confidence in the Dip Buyers Has Weakened

The Confidence in the Dip Buyers Has Weakened

The bears are likely to be increasingly bold if there's a failed bounce.

This 'Correction' May Turn Out to Be Another Dud

This 'Correction' May Turn Out to Be Another Dud

Once the dip buying starts it becomes self-reinforcing.

The Nature of Markets

The Nature of Markets

The best thing you can do right now is work on shopping lists of potential buys.

Biotech Viking Therapeutics Could Double From Here -- But Not Without Risk

Biotech Viking Therapeutics Could Double From Here -- But Not Without Risk

Interest and volume in the stock picked up in September and continues to build.